<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05009069</url>
  </required_header>
  <id_info>
    <org_study_id>ML43050</org_study_id>
    <nct_id>NCT05009069</nct_id>
  </id_info>
  <brief_title>A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer</brief_title>
  <official_title>A Phase II, Randomized, Open Label, Parallel-group Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of atezolizumab plus tiragolumab or&#xD;
      atezolizumab alone following neoadjuvant chemoradiotherapy (nCRT) in participants with&#xD;
      locally advanced rectal cancer (LARC). The study consists of a safety run-in phase and a&#xD;
      randomization phase. Participants enrolled in the safety run-in phase will receive&#xD;
      atezolizumab + tiragolumab following nCRT. Upon determination of the safety of the treatment&#xD;
      regimen, the study will be proceed to the randomization phase. Participants will be&#xD;
      randomized in a 1:1 ratio to the atezolizumab + tiragolumab arm or atezolizumab arm.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 18, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Pathological Complete Response (pCR)</measure>
    <time_frame>At Week 16, Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With R0 Resection</measure>
    <time_frame>At Week 16, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) Before Surgery</measure>
    <time_frame>At Week 16, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One/Two/Three-year Relapse-free Survival (1/2/3-y RFS) Rate</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>One/Two/Three-year Event-free Survival (1/2/3-y EFS) Rate</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With pCR in Subgroup Population With PD-L1/ PVR/TIGIT Positive Expression</measure>
    <time_frame>At Week 16, Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1/2/3-y Disease-free Survival (DFS) Rate in Subgroup Population With PD-L1/ PVR/TIGIT Positive Expression</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1/2/3-y EFS Rate in Subgroup Population With PD-L1/ PVR/TIGIT Positive Expression</measure>
    <time_frame>Year 1, Year 2, Year 3</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>Up to 40 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Rectal Neoplasms</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.&#xD;
Day 1 of Weeks 8, 11 and 14: Atezolizumab plus tiragolumab (Day 1 of each 21-day cycle for 3 cycles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Weeks 1-5: Radiotherapy to the pelvis on Days 1-5 every week. Chemotherapy: Capecitabine or fluorouracil (5-FU) 5 days/week during radiotherapy.&#xD;
Day 1 of Weeks 8, 11 and 14: Atezolizumab (Day 1 of each 21-day cycle for 3 cycles).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Weeks 1-5: 45-50.4Gy in 25-28 fractions to the pelvis on Days 1-5 every week.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Weeks 1-5: Capecitabine 825 mg/m^2 orally twice daily (bid) 5 days/week during radiotherapy.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Weeks 1-5: fluorouracil (5-FU) 225 mg/m^2 intravenously (IV) over 24 hours 5 days/week during radiotherapy.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Weeks 8, 11 and 14: Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle for 3 cycles.</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiragolumab</intervention_name>
    <description>Weeks 8, 11 and 14: Tiragolumab 600 mg IV on Day 1 of each 21-day cycle for 3 cycles.</description>
    <arm_group_label>Atezolizumab + Tiragolumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of adenocarcinoma of the rectum&#xD;
&#xD;
          -  Resectable locally advanced rectal cancer, with clinical stage as cT3N+M0 or cT4NanyM0&#xD;
             per American Joint Committee on Cancer (AJCC)/ International Union Against Cancer&#xD;
             (UICC) 8th edition&#xD;
&#xD;
          -  The inferior margin of the tumor â‰¤10cm from the anal verge&#xD;
&#xD;
          -  No prior anti-cancer treatment for rectal cancer&#xD;
&#xD;
          -  Availability of a representative tumor specimen that is suitable for pathological&#xD;
             evaluation and biomarker expression analysis&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance status (PS) of 0 or 1&#xD;
&#xD;
          -  At least one measurable lesion per Response Evaluation Criteria in Solid Tumors&#xD;
             (RESIST) v1.1&#xD;
&#xD;
          -  Adequate hematologic and end-organ function&#xD;
&#xD;
          -  For patients receiving therapeutic anticoagulation: stable anticoagulant regimen&#xD;
&#xD;
          -  Negative HIV test at screening&#xD;
&#xD;
          -  For women of childbearing potential: agreement to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use contraception, and agreement to refrain from donating&#xD;
             eggs for at least 5 months after the final dose of atezolizumab and for 90 days after&#xD;
             the final dose of tiragolumab, for 6 months after the final dose of capecitabine, for&#xD;
             6 months after the final dose of 5-FU&#xD;
&#xD;
          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use&#xD;
             contraceptive methods and agreement to refrain from donating sperm for at least 90&#xD;
             days after the final dose of tiragolumab, 3 months after final dose of capecitabine,&#xD;
             for 6 months after the final dose of 5-FU.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of metastatic disease&#xD;
&#xD;
          -  Histology consistent with small cell carcinoma, squamous carcinoma, or mixed carcinoma&#xD;
&#xD;
          -  Presence of synchronous colorectal cancer&#xD;
&#xD;
          -  Presence of obstruction or imminent obstruction&#xD;
&#xD;
          -  Clinical symptoms or radiological suspicion of bowel perforation&#xD;
&#xD;
          -  Not eligible for long-course radiotherapy&#xD;
&#xD;
          -  History of malignancies other than rectal cancer within 3 years prior to screening&#xD;
             with the exception of those with a negligible risk of metastasis or death&#xD;
&#xD;
          -  Active or history of autoimmune disease or immune deficiency&#xD;
&#xD;
          -  Significant cardiovascular disease&#xD;
&#xD;
          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced&#xD;
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening&#xD;
             chest computed tomography (CT) scan&#xD;
&#xD;
          -  Severe chronic or active infection within 4 weeks prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment&#xD;
&#xD;
          -  Uncontrolled tumor-related pain&#xD;
&#xD;
          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures&#xD;
&#xD;
          -  Uncontrolled or symptomatic hypercalcemia&#xD;
&#xD;
          -  Uncontrolled diabetes or Grade â‰¥ 2 abnormalities in potassium, sodium, despite&#xD;
             standard medical management within 14 days prior to initiation of study treatment&#xD;
&#xD;
          -  Prior treatment with CD137 agonists, T-cell co-stimulating, or immune checkpoint&#xD;
             blockade therapies, including anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-TIGIT&#xD;
             therapeutic antibodies&#xD;
&#xD;
          -  Treatment with systemic immunostimulatory agents&#xD;
&#xD;
          -  Treatment with systemic immunosuppressive medication&#xD;
&#xD;
          -  Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Major surgical procedure or significant traumatic injury within 28 days prior to&#xD;
             initiation of study treatment, or abdominal surgery, abdominal interventions or&#xD;
             significant abdominal traumatic injury within 60 days prior to initiation of study&#xD;
             treatment&#xD;
&#xD;
          -  Any other disease, medical condition or abnormality, metabolic dysfunction, alcohol or&#xD;
             drug abuse or dependence, physical examination finding, clinical laboratory finding&#xD;
             that contraindicates the use of an investigational drug, may affect the interpretation&#xD;
             of the results, or may render the participant at high risk from treatment&#xD;
             complications&#xD;
&#xD;
          -  Treatment with any other investigational agent with therapeutic intent within 28 days&#xD;
             prior to study treatment initiation&#xD;
&#xD;
          -  History of severe allergic anaphylactic reactions to chimeric or humanized antibodies&#xD;
             or fusion proteins&#xD;
&#xD;
          -  History of allergic reactions to chemotherapy drugs (5-FU and capecitabine)&#xD;
&#xD;
          -  Known dihydropyrimidine dehydrogenase (DPD) deficiency or history of severe and&#xD;
             unexpected reactions to fluoropyrimidine therapy in participants selected to receive&#xD;
             capecitabine&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: ML43050 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. Only)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510655</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou City</city>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

